Sesen Bio, Inc. (NASDAQ:SESN) headquartered in Cambridge, will host a conference call for the investment community to discuss the 3Q20 earnings result on 9th November 2020 at 8:00 AM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit www.sesenbio.com
Earnings Expectation
Sesen Bio, Inc. is expected to report third quarter earnings results, before market open, on Monday 9th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.08 per share. Looking ahead, the full year loss are expected at $ 0.05 per share.
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment of cancer. The companys lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a systemically-administered product candidate, which is in Phase I/II clinical trials for use in the treatment of various types of EpCAM-positive solid tumors. It is also developing Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of high-risk NMIBC; and Vicinium in combination with AstraZenecas checkpoint inhibitor that is in Phase I/IIa clinical trials for the treatment of squamous cell carcinoma of the head and neck.
